Analytical Ultracentrifugation (AUC) has been a staple in the biopharmaceutical industry to analyze aggregation and higher order structure in protein drug products. With the recent boom in cell and gene therapies using gene delivery vectors, new avenues for AUC-based characterization and QC lot release methodologies are now available. View this webinar for a discussion on the new parameters of AUC analysis and how to maintain conformation to ICH guidelines. Learn how to bridge the gap from traditional methods to a high-quality AUC platform for your AAV program.
In the second part of this webinar, we will discuss the Aiforia neural network (NN), which has been trained to recognize negatively stained AAV capsids in TEM images. The NN is also able to sort capsids based on the amount of stain within the structure. Electron-lucient (unstained) homogenous capsids are classified as full, those with an electron-dense core (stained) are classified as empty, and capsids containing a non-homogeneous staining pattern are classified as intermediate. This sorting of empty, full, and intermediate capsids in the image allows for the ratio to be estimated for a given sample.
Christopher Sucato, PhD
Associate Director, Biophysical Characterization
Cynthia Swanson, MS
Associate Research Scientist
View the other webinars in this series:
- A Platform Approach for Analytical Methods to Support Adeno-Associated Virus (AAV) Gene Therapy Products (On Demand)
- Advanced Mass Spectrometry-Based Characterization of Adeno-Associated Viruses and Next Generation Biologics (On Demand)
- Viral Clearance Challenges for Gene Therapy Products (On Demand)
During this time of uncertainty, we are focused on providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.